Cancer

Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Nov. 12, 2024 /PRNewswire/ -- The global artificial intelligence (AI) in drug discovery market is projected to…

1 year ago

Enspectra Health’s groundbreaking cross-modal platform pioneers transformation in the field of skin health

A new publication in a Nature Research journal describes the novel technology behind the recently FDA-cleared imaging modality, a major…

1 year ago

Visage Transforms Imaging to the Cloud at RSNA 2024

Visage innovates with Visage Chat, Visage 7 | AI and more SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Visage Imaging,…

1 year ago

Canopy to be Highlighted in Two Studies at ASH 2024

Research Shows Potential to Improve Time on Treatment and Detection of High-Risk Toxicities for Blood Cancer Patients Using the Canopy…

1 year ago

Compugen Reports Third Quarter 2024 Results

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors…

1 year ago

Philips Spectral CT 7500 RT, world’s first spectral 4DCT respiratory-gated imaging receives FDA 510(k) clearance

Philips Spectral CT 7500 RT Spectral CT 7500 RT clinical November 12, 2024 Designed specifically for use in radiation oncology,…

1 year ago

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data…

1 year ago

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC,…

1 year ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…

1 year ago